News Feed Opinion Career Insight Dialogues Blog
Positive Societies Drugs Stories History
Talha Badar: Moving immunotherapy upfront in B-cell ALL
Photo taken from Talha Badar/Twitter
25/10/2023 18:04

Talha Badar: Moving immunotherapy upfront in B-cell ALL

Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on Twitter:
“Weekend reading Tweetorial.

Moving immunotherapy upfront in B-cell ALL.

Due to increased understanding of disease biology, resistance/toxicity from chemotherapy, field is moving towards early introduction of targeted molecule and immunotherapy.

INO, an anti-CD22 Ab was approved for RR ALL based on INO-VATE study:

  • higher CR rate 81% vs 29%; P < .001); MRD 78% vs 28% after SOC P < .001.

Among the patients who received allo-HSCT after INO, 22% had VOD

DOI: 10.1056/NEJMoa1509277

Phase II study of InO plus mini hyper CVD upfront for B-cell ALL; 2 yrs PFS was 59% and OS 66%.

Click here for the article.

Several trials now incorporating InO ealry in Rx of B-cell ALL below.

 

Blinatumomab (CD3-CD19 bispecific) was approved for RR B-cell ALL based on positive results of PIII:

  • higher ORR 44% vs. 25%, P<0.001
  • mOS 7.7 vs 4.0 mo.

DOI: 10.1056/NEJMoa1609783

HyperCVAD plus sequential Blina for Ph-ve B-cell ALL.

4 # of HyperCVAD leads to 4 # of Blina leads to  3 cycles of POMP alternating with 1 cycle of Blina for 15 cycles.

  • 38 pts: CR 100%,
  • MRD -ve 97%, 3-yr OS 81%

Impressive results, including pts with HR disease.

10.1016/S2352-3026(22)00285-X

Blina followed by POMP maintenance in elderly with Ph-ve B cell ALL (SWOG 1318).

29 pts, median age 75 yrs, poor risk 34%.

CR 66%, 3 yrs DFS and OS 37% each

DOI: 10.1200/JCO.21.01766

E1910 trial incorporating Blina with chemotherapy in MRD -ve B-cell ALL.
Primary endpoint was OS and it was met!

Chemotherapy free Rx for elderly B-cell ALL: InO and Blina for older:
Alliance A041703
Phase II trial of induction InO then blina for older adults with newly-diagnosed (ND), Ph-, B-ALL.

  • 33 pts, CR after course II 97%, 1 yr EFS 75%, 1 yr OS 84%.

Click here for the article.

Several trials now incorporating Blina early in Rx of B-cell ALL below.

Chemo-free regimen for Ph+ve ALL with upfront immunotherapy.

Excellent responses with 2 yrs OS > 90%.

Click here for the article.

Summary:

It is high time to incorporate immunotherapy upfront in Rx of B-cell ALL:

  • Less toxic
  • More effective with durable responses
  • Effective in high risk pts. “
ALL cancer OncoDaily Oncology Talha Badar
Blog
16:27 30/11/23
David Lubarsky: 4 Ms
Drugs
16:23 30/11/23
Mariana Brandao: My comment on the ARTEMIDE-01 phase I trial testing a new bispecific anti-PD-1/anti-TIGIT antibody called Rilvegostomig
Blog
16:18 30/11/23
Do you want to be part of the first-ever national cancer innovation accelerator initiative with public support from The White House? - CancerX Moonshot
Opinion
16:11 30/11/23
Gavin Preston: If thinking of going into medicine to get rich, forget it
Blog
16:04 30/11/23
Two charities will co-fund a major £5.5 million research programme called Stratified Medicine Paediatrics 2 - The Institute of Cancer Research
Blog
15:58 30/11/23
Aju Mathew: Rising numbers of hepatocellular carcinoma in India
Blog
15:51 30/11/23
Bente Mikkelsen: This is the latest edition of the IARC handbook series and covers the topic of oral cancer prevention
Blog
15:43 30/11/23
Rebekka K. Schneider: Our research will be supported by an European Research Council (ERC) consolidator grant
Blog
15:39 30/11/23
Otilia Ciobanu: Review on the potential of targeting the subventricular zone for improved outcomes in high-grade gliomas
Blog
15:33 30/11/23
Andre Lopes Carvalho: I had the incredible opportunity to celebrate the 20th anniversary of ZORA
Drugs
15:29 30/11/23
David Steensma: Randomized STIMULUS-MDS1 trial didn't meet endpoint
Blog
15:25 30/11/23
Monica M. Bertagnolli: One of my priorities is ensuring all people are represented in clinical trials
Insight
Positive
Societies
Career